Research Studies » Obsessive-Compulsive Disorder (OCD)
BHV-4157 in Adult
Subjects With
Obsessive Compulsive
Disorder
GLUTAMATES ROLE IN THE BRAIN AND OCD
Various animal and human studies have shown evidence that in OCD there is a hyperactivity in the Cortex, Striatum and Thalamus loop, the "CST loop" which is impaired by glutamate. We believe if we directly modulated that loop with glutamate agents we could possibly improve the treatment for patients with OCD. The current study uses trigriluzole, a glutumate modulator.
ABOUT TRIGRILUZOLE
Trigriluzole, a drug which modulates glutamate, was developed as a prodrug of riluzole. A prodrug is an inactive medication that is converted into an active form of drug once it has been ingested. After a patient takes trigriluzole, the body converts it into the active drug, riluzole. Riluzole was approved by the FDA in 1995 for the treatment of ALS, and remains the only FDA approved drug for this disease. Additionally, riluzole has been studied in clinical trials in patients with OCD with promising results. Because riluzole has been used for decades, it has a well-established safety and tolerability profile. Trigriluzole offers the potential for significant advantages over riluzole, and was developed to improve some of the limitations of riluzole. Riluzole is dosed twice daily, whereas trigriluzole is dosed once daily. Additionally, patients need to fast before and after taking riluzole, as food can affect the its absorption. Trigriluzole does not require any special meal restrictions. Trigriluzole was also designed to be metabolized differently in the body, and therefore potentially have a better safety and tolerability profile than riluzole.
Adults between the ages of 18 and 65 years old who have been diagnosed with OCD may qualify for a research study.
Qualified participants include:
Qualified candidates who participate will receive study-related care at no cost and receive compensation for travel.
Printable Clinical Research Flyer